| Press
releases |
|
|
|
|
Lupin Net Profit up 77% at Rs. 400
mn; Net Sales up 10% at
Rs. 2629 mn; Equity Ratio improves to 0.85:1 |
(20
Jan 2004) |
|
|
Lupin Limited net profit for the quarter ended 31st Dec 2003 increased by 77% to Rs.400 mn from Rs.227
mn, a year ago. Sales (net of excise duty) during the quarter under review stood at Rs.2,629 mn a growth of 10.2% over the corresponding period a year ago. |
|
Full
release
|
|
|
|
Lupin appoints new President for Asia
Pacific,
Latin America |
(8
Jan 2004) |
|
| Lupin has appointed Vinod Dhawan as
President-Business Development (Latin America, Japan, Australia, and New Zealand). |
|
Full
release
|
|
|
|
Lupin launches novel cholesterol-fighter EZEDOC |
(2
Jan 2004) |
|
| Lupin today announced the launch of EZEDOC (ezetimibe), a specialty drug that targets India’s fast-growing cholesterol management segment. Taken along with a statin such as Lupin’s TONACT (atorvastatin), EZEDOC brings about a further reduction in “bad” cholesterol and raises “good” cholesterol. Available data clearly shows a synergy of ezetimibe and commonly used statins to manage cholesterol. |
|
Full
release |
|
|
|
Archives
|
|
|
